United Therapeutics/$UTHR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About United Therapeutics
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Ticker
$UTHR
Sector
Primary listing
Employees
1,305
Headquarters
Website
UTHR Metrics
BasicAdvanced
$20B
17.21
$26.38
0.87
-
Price and volume
Market cap
$20B
Beta
0.87
52-week high
$479.50
52-week low
$266.98
Average daily volume
672K
Financial strength
Current ratio
6.396
Quick ratio
5.611
Interest coverage (TTM)
62.62%
Profitability
EBITDA (TTM)
1,604.1
Gross margin (TTM)
88.59%
Net profit margin (TTM)
40.65%
Operating margin (TTM)
48.64%
Effective tax rate (TTM)
23.69%
Revenue per employee (TTM)
$2,400,000
Management effectiveness
Return on assets (TTM)
13.14%
Return on equity (TTM)
20.04%
Valuation
Price to earnings (TTM)
17.212
Price to revenue (TTM)
6.483
Price to book
2.96
Price to tangible book (TTM)
3.01
Price to free cash flow (TTM)
18.168
Free cash flow yield (TTM)
5.50%
Free cash flow per share (TTM)
24.989
Growth
Revenue change (TTM)
13.50%
Earnings per share change (TTM)
16.08%
3-year revenue growth (CAGR)
18.92%
10-year revenue growth (CAGR)
8.32%
3-year earnings per share growth (CAGR)
21.51%
10-year earnings per share growth (CAGR)
7.57%
What the Analysts think about UTHR
Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.
Bulls say / Bears say
United Therapeutics reported record Q2 2025 revenue of $799 M, up 12% year-over-year—the 12th consecutive quarter of double-digit growth—and authorized a $1 B share repurchase, underscoring strong financial confidence (TipRanks).
In Q1 2025, total revenues rose 17% to $794 M, driving operating cash flow up 22% to $461 M and leaving cash and investments exceeding $5 B, reflecting robust liquidity (Investing.com).
The Phase 3 TETON-2 trial of nebulized Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint—improving forced vital capacity by 95.6 mL over placebo at Week 52—paving the way for a high-value label expansion (Nasdaq).
Operating expenses climbed 28% in Q1 2025 to $412 M—driven by a 43% surge in R&D spending, a $71.8 M litigation accrual, and planned capital expenditures of $750 M through 2027—potentially pressuring margins and free cash flow (Panabee).
In Q2 2025, GAAP revenue of $798.6 M fell short of consensus by $3.3 M and EPS of $6.41 missed estimates by $0.88, indicating execution risks against lofty Wall Street expectations (The Motley Fool).
In Q3 2025, revenues from nebulized Tyvaso declined 11% year-over-year—mainly due to higher gross-to-net deductions and lower volumes—highlighting pricing headwinds and competitive pressures for the legacy delivery format (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 7 Nov 2025.
UTHR Financial Performance
Revenues and expenses
UTHR Earnings Performance
Company profitability
UTHR News
AllArticlesVideos
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
Business Wire4 days ago
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
Business Wire1 week ago
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for United Therapeutics stock?
United Therapeutics (UTHR) has a market cap of $20B as of November 07, 2025.
What is the P/E ratio for United Therapeutics stock?
The price to earnings (P/E) ratio for United Therapeutics (UTHR) stock is 17.21 as of November 07, 2025.
Does United Therapeutics stock pay dividends?
No, United Therapeutics (UTHR) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next United Therapeutics dividend payment date?
United Therapeutics (UTHR) stock does not pay dividends to its shareholders.
What is the beta indicator for United Therapeutics?
United Therapeutics (UTHR) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.